Regeneron Pharmaceuticals faced significant selling pressure as investors reacted to its latest partnership deal with Sanofi.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) fell 6.71% yesterday, closing at CA$726.47. This decline came amid investor disappointment over the terms of a newly expanded collaboration with Sanofi.
Investor takeaway: Investors are concerned that the new agreement with Sanofi may dilute Regeneron's long-term profit potential, particularly regarding its blockbuster drug, Dupixent.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$75.69B
P/E
18.2x
Div. yield
0.50%
Div. / share
$3.64
52W high
$859.34
52W low
$538.24
1W change
-3.43%
Beta
0.19
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 5, 2026
Wall Street analysts forecast REGN stock price to rise 17.4% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$853.19
+17.4% Upside
Previously C$850.88 on Sep 25, 2026
Current Price
C$726.47
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.1%
Annualized
90-Day Vol
29.7%
Annualized
Trend (90d)
+37.9%
Annualized drift
90d Mean
C$831.85
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$760.02 | C$689.91 – C$837.26 |
| 60 trading days | C$795.12 | C$693.41 – C$911.75 |
| 90 trading days | C$831.85 | C$703.46 – C$983.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
The expanded collaboration with Sanofi could lead to new therapies that enhance Regeneron's product pipeline and revenue streams over time.
Bear case
The new deal does not improve the economic terms for Dupixent, raising concerns about future profitability and potentially shaking investor confidence in Regeneron's growth prospects.
Market Reaction to Partnership News
The market reacted sharply to Regeneron's announcement of an expanded collaboration with Sanofi, which includes an upfront payment of $1 billion and potential milestone payments up to $7 billion. However, investors were disappointed that the terms did not enhance the profit-sharing structure for Dupixent, a drug that has been a cornerstone of Regeneron's revenue.
Advertisement
Concerns Over Long-Term Profitability
Investors are worried that the new agreement will dilute Regeneron's long-term profit margins. The deal requires both companies to share development costs and profits equally, which some analysts believe could limit Regeneron's ability to capitalize on its next-generation immunology therapies.
Broader Market Context
While the overall market saw gains, with the Nasdaq Composite rising 1.2%, the healthcare sector faced challenges, particularly Regeneron, which was among the top losers. The S&P 500 Health Care Sector Index dropped 2.66% for the week, indicating a broader trend of caution among investors in the healthcare space.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
